Solara Active Pharma Sciences Limited — Investor Meet, 29-07-2026: Analysts/Institutional Investor Meet/Con. Call Updates

Solara Q1 FY27 results reflect strong execution. Revenue rose 20% YoY to 384 Cr, with EBITDA up 10% YoY to 63.5 Cr, and PAT climbing 55% YoY to 16.3 Cr—the highest in 18 quarters. The base business revenue grew 24% to 307 Cr. Ibuprofen continues to face profitability challenges, posting a negative 12% EBITDA margin. Net debt significantly reduced by 135 Cr to 479 Cr. Management priorities include expanding the base business, driving operational efficiency through debottlenecking, and optimizing working capital. An update on the Ibuprofen strategic review is expected by H1 FY27. Solara remains confident in its path toward profitable growth and aims to be net debt-free by FY29.